226 related articles for article (PubMed ID: 28210154)
21. A Ras destabilizer KYA1797K overcomes the resistance of EGFR tyrosine kinase inhibitor in KRAS-mutated non-small cell lung cancer.
Park J; Cho YH; Shin WJ; Lee SK; Lee J; Kim T; Cha PH; Yang JS; Cho J; Min DS; Han G; Lee HY; Choi KY
Sci Rep; 2019 Jan; 9(1):648. PubMed ID: 30679620
[TBL] [Abstract][Full Text] [Related]
22. Relationships among
Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
[TBL] [Abstract][Full Text] [Related]
23. Epiregulin contributes to breast tumorigenesis through regulating matrix metalloproteinase 1 and promoting cell survival.
Farooqui M; Bohrer LR; Brady NJ; Chuntova P; Kemp SE; Wardwell CT; Nelson AC; Schwertfeger KL
Mol Cancer; 2015 Jul; 14():138. PubMed ID: 26215578
[TBL] [Abstract][Full Text] [Related]
24. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
25. PGE2/EP3/SRC signaling induces EGFR nuclear translocation and growth through EGFR ligands release in lung adenocarcinoma cells.
Bazzani L; Donnini S; Finetti F; Christofori G; Ziche M
Oncotarget; 2017 May; 8(19):31270-31287. PubMed ID: 28415726
[TBL] [Abstract][Full Text] [Related]
26. Functional suppression of Epiregulin impairs angiogenesis and aggravates left ventricular remodeling by disrupting the extracellular-signal-regulated kinase1/2 signaling pathway in rats after acute myocardial infarction.
Cai Y; Xie KL; Wu HL; Wu K
J Cell Physiol; 2019 Aug; 234(10):18653-18665. PubMed ID: 31062344
[TBL] [Abstract][Full Text] [Related]
27. Epiregulin-dependent amphiregulin expression and ERBB2 signaling are involved in luteinizing hormone-induced paracrine signaling pathways in mouse ovary.
Kim K; Lee H; Threadgill DW; Lee D
Biochem Biophys Res Commun; 2011 Feb; 405(2):319-24. PubMed ID: 21237132
[TBL] [Abstract][Full Text] [Related]
28. mTORC1 upregulation via ERK-dependent gene expression change confers intrinsic resistance to MEK inhibitors in oncogenic KRas-mutant cancer cells.
Komatsu N; Fujita Y; Matsuda M; Aoki K
Oncogene; 2015 Nov; 34(45):5607-16. PubMed ID: 25703330
[TBL] [Abstract][Full Text] [Related]
29. Targeting oncogenic KRAS in non-small cell lung cancer cells by phenformin inhibits growth and angiogenesis.
Wang ZD; Wei SQ; Wang QY
Am J Cancer Res; 2015; 5(11):3339-49. PubMed ID: 26807315
[TBL] [Abstract][Full Text] [Related]
30. An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer.
Wang H; Lv Q; Xu Y; Cai Z; Zheng J; Cheng X; Dai Y; Jänne PA; Ambrogio C; Köhler J
EBioMedicine; 2019 Nov; 49():106-117. PubMed ID: 31668570
[TBL] [Abstract][Full Text] [Related]
31. BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer.
Ku BM; Jho EH; Bae YH; Sun JM; Ahn JS; Park K; Ahn MJ
Invest New Drugs; 2015 Feb; 33(1):12-21. PubMed ID: 25342139
[TBL] [Abstract][Full Text] [Related]
32. KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: implication for combinatorial approach.
Yoon YK; Kim HP; Han SW; Oh DY; Im SA; Bang YJ; Kim TY
Mol Carcinog; 2010 Apr; 49(4):353-62. PubMed ID: 20358631
[TBL] [Abstract][Full Text] [Related]
33. Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers.
Lee SY; Kim MJ; Jin G; Yoo SS; Park JY; Choi JE; Jeon HS; Cho S; Lee EB; Cha SI; Park TI; Kim CH; Jung TH; Park JY
J Thorac Oncol; 2010 Nov; 5(11):1734-40. PubMed ID: 20881644
[TBL] [Abstract][Full Text] [Related]
34.
Kuramochi H; Nakajima GO; Hayashi K; Araida T; Yamamoto M
Anticancer Res; 2019 Sep; 39(9):4729-4736. PubMed ID: 31519572
[TBL] [Abstract][Full Text] [Related]
35. Induction of apically mistrafficked epiregulin disrupts epithelial polarity via aberrant EGFR signaling.
Singh B; Bogatcheva G; Krystofiak E; McKinley ET; Hill S; Rose KL; Higginbotham JN; Coffey RJ
J Cell Sci; 2021 Sep; 134(18):. PubMed ID: 34406412
[TBL] [Abstract][Full Text] [Related]
36. Targeting oncogenic
Yang L; Li Z; Binzel DW; Guo P; Williams TM
Mol Ther Nucleic Acids; 2023 Sep; 33():559-571. PubMed ID: 37637206
[No Abstract] [Full Text] [Related]
37. Epiregulin reprograms cancer-associated fibroblasts and facilitates oral squamous cell carcinoma invasion via JAK2-STAT3 pathway.
Wang Y; Jing Y; Ding L; Zhang X; Song Y; Chen S; Zhao X; Huang X; Pu Y; Wang Z; Ni Y; Hu Q
J Exp Clin Cancer Res; 2019 Jun; 38(1):274. PubMed ID: 31234944
[TBL] [Abstract][Full Text] [Related]
38. Epiregulin is required for lung tumor promotion in a murine two-stage carcinogenesis model.
Bauer AK; Velmurugan K; Xiong KN; Alexander CM; Xiong J; Brooks R
Mol Carcinog; 2017 Jan; 56(1):94-105. PubMed ID: 26894620
[TBL] [Abstract][Full Text] [Related]
39. Dual inhibition of MEK and p38 impairs tumor growth in
Sunaga N; Miura Y; Tsukagoshi Y; Kasahara N; Masuda T; Sakurai R; Kaira K; Hisada T
Oncol Lett; 2019 Mar; 17(3):3569-3575. PubMed ID: 30867799
[TBL] [Abstract][Full Text] [Related]
40. Interferon/STAT1 and neuregulin signaling pathways are exploratory biomarkers of cetuximab (Erbitux®) efficacy in KRAS wild-type squamous carcinomas: a pathway-based analysis of whole human-genome microarray data from cetuximab-adapted tumor cell-line models.
Oliveras-Ferraros C; Vazquez-Martin A; Queralt B; Adrados M; Ortiz R; Cufí S; Hernández-Yagüe X; Guardeño R; Báez L; Martin-Castillo B; Pérez-Martínez MC; Lopez-Bonet E; De Llorens R; Bernadó L; Brunet J; Menendez JA
Int J Oncol; 2011 Dec; 39(6):1455-79. PubMed ID: 21833472
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
